Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
about
Progress in treatment of ANCA-associated vasculitisInterventions for renal vasculitis in adultsImmunosuppressive treatment for non-systemic vasculitic neuropathyThe Prevalence and Management of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in ChinaRecent advances in understanding and treating vasculitisHydralazine-induced pauci-immune glomerulonephritis: intriguing case series with misleading diagnosesRecent advances in anti-neutrophil cytoplasmic antibody-associated vasculitisSpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesCellular targeting in autoimmunityCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Updates in ANCA-associated vasculitisConditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitidesTreatment of renal manifestations of ANCA-associated vasculitis.[Long-term data from the CYCLOPS study].Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.Interventions for renal vasculitis in adults. A systematic review.ANCA-associated vasculitis in childhood: recent advances.Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans.Sequential strokes in a hyperacute stroke unit.Management of ANCA-associated vasculitis: Current trends and future prospectsEfficacy of remission-induction regimens for ANCA-associated vasculitis.Cyclophosphamide and lupus nephritis: when, how, for how long?Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis.Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysisGranulomatosis with polyangiitis (Wegener's) as a necrotizing gingivitis mimic: a case report.Pharmacotherapy for uveitis: current management and emerging therapy.Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.Variability of the impact of adverse events on physicians' decision makingPlasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysisCurrent therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximabUrinary immunoglobulin G to albumin ratio and N-Acetyl-Beta-D-Glucosaminidase as early predictors of therapeutic response in ANCA-associated glomerulonephritis.Successful induction of granulomatosis with polyangiitis with tacrolimus.Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.Rituximab versus cyclophosphamide for ANCA-associated vasculitis.Central nervous system vasculitis: still more questions than answers.American Society of Nephrology quiz and questionnaire 2014: glomerular diseasesRenal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials.
P2860
Q21195258-F9D8B05C-EE3B-48A0-9B12-8EBA0BC1707BQ24187038-20BEFCA1-97EF-4322-8312-F4367C5E87BAQ24246358-DE27DF21-3496-491A-9119-0AE72A25A009Q26740453-839C480D-D01B-4605-85F8-979EB0E0708DQ26747046-ABD6D678-17CB-4108-8B91-669812E8C85CQ26749168-A0810400-F5E0-4E98-BAE8-CA11C560A4D1Q26751357-AB1F3C83-B3BE-43D1-B36C-240745AD9A70Q26776308-A42BF59C-A4A9-457E-BD13-3C886B0F1F35Q26824580-56E553D2-A021-4CBE-82DF-D20A8F758BD5Q27025692-3A66710C-BCF6-4201-BA89-4E99DA37313FQ28069897-D410DD36-976A-447B-BC24-C519DEBD5F21Q28393792-FBE27D10-FA32-4274-A714-1B7C48627A35Q30486655-A69EC369-34FA-49AC-9FAB-317C0AD61693Q30611654-3A123273-A813-483A-BC47-B07E0A82444BQ30696868-37CD7D64-3A73-4D9A-89F5-E4C83A0F4282Q30849537-0039C49B-FD39-415D-BA28-8EDCB558B19BQ33614376-56B669FA-3837-4474-9FE2-1880C3FF2418Q33644574-92A431F8-DF90-4A8A-B743-C10289AFEE75Q33771970-804B1D04-66FF-4554-9003-AC75FD4B410EQ33862188-0B39D0C7-6B8B-4C45-BA4F-75BE10950952Q33908125-1A281D08-64EF-4AF1-BD51-1FAB5B9E95E4Q33947599-063EA7B1-CC6E-4D83-8CBB-2ABF32415F48Q34037683-1B142AB0-8A2A-48B7-A70E-C7D3463513E3Q34095231-BF1B594C-A4D3-4240-B69A-3CF0300D4D9FQ34124668-F45E018B-3601-4027-A7E3-EDC3C5FBCC34Q34124711-B8AD1AC2-7E07-4465-96DE-EF52C2143F69Q34157764-C436D2D1-2348-4C62-9254-6CEC330DD296Q34212522-CBA78B17-718F-434B-AD18-C89D355F29CCQ34274075-EEEB53AC-EB6E-4EED-8B40-813B8E07B5DEQ34500502-53E70FEC-4DC8-4D5A-887F-8E4E48A36E25Q34538062-34FFF913-1416-4571-8885-5C52986357BDQ34708735-68ADB2FE-0702-401E-8408-A90203020EACQ35065425-BC753408-D529-4600-8B67-3A6E04DF1F49Q35069739-F27F4FA3-59DF-4805-B2C4-5D6B2660BF27Q35071121-D1D1C0D2-C565-4E0E-A349-6D6C03C4650AQ35082362-5BEED117-CEE5-4F6E-BDBC-D213B9D55196Q35109118-CF489736-9932-4A95-9CA1-EAAD28CE25C0Q35151866-2E5AC084-BBFE-4963-A2EF-4E76E0EA5815Q35278674-12C55807-C05C-4B2F-9807-22378E9FEDDBQ35363729-198FE6C0-3C5F-4C29-9587-BAA31A33AE12
P2860
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Pulse versus daily oral cyclop ...... asculitis: a randomized trial.
@en
Pulse versus daily oral cyclop ...... asculitis: a randomized trial.
@nl
type
label
Pulse versus daily oral cyclop ...... asculitis: a randomized trial.
@en
Pulse versus daily oral cyclop ...... asculitis: a randomized trial.
@nl
prefLabel
Pulse versus daily oral cyclop ...... asculitis: a randomized trial.
@en
Pulse versus daily oral cyclop ...... asculitis: a randomized trial.
@nl
P2093
P1476
Pulse versus daily oral cyclop ...... asculitis: a randomized trial.
@en
P2093
Caroline O S Savage
Charles D Pusey
David R W Jayne
EUVAS (European Vasculitis Study Group)
Gina Gregorini
Kerstin Westman
Kirsten de Groot
Lorraine Harper
Luis Felipe Flores Suarez
Niels Rasmussen
P304
P356
10.7326/0003-4819-150-10-200905190-00004
P407
P577
2009-05-01T00:00:00Z